Skip to main content
Clinical Trials/NCT00553605
NCT00553605
Completed
Phase 4

A Double-Blind, Double-Dummy, Randomized, Multicenter Study Comparing The Analgesic Efficacy And Safety Of Parecoxib 40mg I.V. To Ketoprofen 100mg I.V. In Renal Colic

Pfizer1 site in 1 country340 target enrollmentJune 2007

Overview

Phase
Phase 4
Intervention
Ketoprofen 100mg
Conditions
Pain
Sponsor
Pfizer
Enrollment
340
Locations
1
Primary Endpoint
Mean Pain Intensity Difference at 30 Minutes (mPID30min)
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This is a multicenter, randomized, double blind, double dummy, comparative, active-controlled trial designed to assess the analgesic activity and safety of intravenous doses of parecoxib 40 mg relative to intravenous doses of ketoprofen 100 mg for the treatment of renal colic in outpatients presenting at emergency room settings. This trial is designed to show non-inferiority of parecoxib related to ketoprofen.

Registry
clinicaltrials.gov
Start Date
June 2007
End Date
June 2009
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Pfizer
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient male or female with a confirmed diagnosis of acute renal colic with moderate to severe pain according to the VAS and Categoric pain scales

Exclusion Criteria

  • The patient has significant renal or hepatic conditions other than uncomplicated kidney stones.
  • The patient has a history of clinically significant hypersensitivity to any NSAIDs, cyclooxygenase inhibitors, analgesics or sulfa medications which has a cross sensitivity to the medications used in this study.

Arms & Interventions

I

Ketoprofen plus placebo parecoxib

Intervention: Ketoprofen 100mg

II

Parecoxib plus placebo ketoprofen

Intervention: Parecoxib 40mg

Outcomes

Primary Outcomes

Mean Pain Intensity Difference at 30 Minutes (mPID30min)

Time Frame: Minute 30

mPID score was obtained by summation of product of length of the interval and difference in pain intensity (PI) divided by summation of length of the interval. Summation was done from zero to 30 minutes. Difference in pain intensity was obtained by subtracting the Pain Intensity Visual Analogue Scale (PI-VAS) at Minute 30 from baseline PI-VAS score. PI-VAS assessed with response to the question "How much pain are you having right now?" on a 100 millimeter (mm) line, with 0 mm=no pain, 100 mm= worst possible pain. mPID score ranged from -100 to 100. Positive score= improved response in pain.

Secondary Outcomes

  • Number of Participants With Response in Pain Intensity(Minute 30)
  • Mean Pain Intensity Difference at 120 Min (mPID120min)(Minute 120)
  • Number of Participants With Pain Relief (PR)(Minute 30, 120)
  • Patient's Global Evaluation of Study Medication(Minute 30, 120)
  • Time-specific Pain Intensity (PI) VAS Score(Baseline, Minute 15, 30, 45, 60, 90, 120)
  • Time-specific Pain Intensity Difference (PID) at Minute 15, 30, 45, 60, 90 and 120(Baseline, Minute 15, 30, 45, 60, 90, 120)
  • Physician's Global Evaluation of Study Medication(Minute 30, 120)
  • Number of Participants With Use of Rescue Medication (RM)(Up to Minute 120)
  • Time-weighted Sum of Pain Relief Score Over 120 Min (TOTPAR120min)(Baseline through Minute 120)

Study Sites (1)

Loading locations...

Similar Trials